INVESKIN’s methodology is based on biotechnological products with high efficacy, containing Epidermal Growth Factor (EGF) and Hyaluronic Acid (HA).
EGF is a scientifically well-known molecule with thousands of clinical studies showing its effectiveness and safety, mainly in dermatological indications.
The challenge lies in its high instability. Without stabilization, growth factors are not effective since their half-life is only 7 hours.
INVES BIOFARM has patented technology to stabilize EGF for years.
Hyaluronic Acid, since its recent biotechnological production, has become an essential molecule in dermatology.
INVESKIN is a brand suitable for all skin types, and its regenerative protocols can be performed throughout the year.
Their research concept arises from an in-depth understanding of the skin and its repair processes, developing specific molecules inherent to our skin in a formulation that guarantees stability and allows trans-epidermal penetration to maintain and repair cellular dysfunction.
BIOSCIENCE APPLIED TO CELL REGENERATION
INVESKIN focuses its efforts on a deep understanding of cutaneous regeneration and cell mitosis processes to develop biomimetic and biocompatible molecules that stimulate tissue repair, thus counteracting dysfunctions caused by intrinsic cellular aging or epigenetic factors.
INVESKIN formulations are based on two elements naturally present in our epidermis, EGF and HA, which are responsible for skin maintenance, regeneration, and functionality processes.
The science behind INVESKIN’s professional protocols is, therefore, based on our skin’s biology.
EFFICACY, PENETRATION, REPAIR
Products designed to penetrate and repair our skin.
Based on the same active principles that nature has placed in our skin for maintenance and repair.
Native molecules of our skin with numerous clinical trials and research: efficacy and safety.
Developed with patented proprietary technology.
Only then can the maximum effectiveness be achieved.
“You will notice the difference in a week; others will notice in two weeks.”
- International biotechnological patent for protein stabilization for dermatological use: EGF, FGF, KGF, etc.
- 2018 Technological Research Award Siglo XXI MADRID
- INVES BIOFARM, EUROPEAN TECHNOLOGY AWARDS PARIS 2019
- Advanced proprietary technology due to the successful acquisition of European research funds.
- Obtained European fund subsidies equivalent to 60,000 hours of R&D.
- In-house research, development, and manufacturing, collaborating on R&D projects with leading specialists and development centers.